Biotech Selects Almac's Interactive Response Platform

Article

A global biotech will be migrating to its newest generation Interactive Response Technology (IRT), platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.

Almac Clinical Technologies, part of the Almac Group, has announced that a global biotechnology company will be migrating to its newest generation Interactive Response Technology (IRT), IXRS® 3 platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.  

Read the full release.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.